Mirvis E, Toumpanakis C, Mandair D, et al. - Researchers undertook this retrospective study to assess peptide receptor radionuclide therapy (PRRT) in patients suffering from bronchial neuroendocrine tumours (NETs), focusing on efficacy, safety and toxicity of PRRT. Participants were managed with at least two cycles of ⁹⁰Yttrium-DOTA−OCTREOTATE and/or ¹⁷⁷Lutetium-DOTA−OCTREOTATE for moderate to well-differentiated typical or atypical bronchial NETs. This study involved 25 patients with bronchial NETs who were managed with PRRT. The median progression-free survival (PFS) and overall survival were estimated to be 17 months and 42 months, respectively. A shorter PFS was observed in relation to high proliferation rate (ki-67 > 20) and low somatostatin receptor uptake (score of 2). In conclusion, PRRT affords a safe therapeutic choice for patients with somatostatin receptor positive bronchial NETs, even for heavily pre-treated patients. PRRT was shown to have similar, if not favorable efficacy vs other systemic treatment choices.